Clinical Trial Update: Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a tailored immunotherapy approach with nivolumab in metastatic or advanced transitional cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Transitional Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Transitional Cell Carcinoma, Advanced Cancer | Phase 2 | Status: UNKNOWN